All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
Interim results of the JULIET trial of CTL019 in R/R DLBCL
Tisagenlecleucel in patients with R/R DLBCL without measurable disease at infusion
Tisagenlecleucel (tis) demonstrates efficacy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) without detectable disease after bridging...
EBMT Debate Session | How to treat R/R DLBCL in 2019? | Part 3 – CAR-T
A Keynote Debate Session on how to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) took place on Tuesday 26 March 2019, during the 45th Annual...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox